Roger Song

Jefferies | Healthcare

Roger Song is an analyst from Jefferies specializing in the Healthcare sector. Ranked #862 out of 4773 analysts, they have issued 16 stock ratings with a success rate of 64.21% and an average return of 54.04%.

With 16 ratings to date, Roger Song is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 64.21% and an average return of 54.04%, highlighting promising potential as their track record develops further.

#862

Out of 4773

16

Total Ratings

+64.21%

Success Rate

+54.04%

Average Return

Recent Ratings Analysis

MANE

Jul 07, 2026

Target

$182.00

Current

$98.97

Performance

-15.27%

Roger Song rated MANE as Buy on Jul 07, 2026, setting a price target of 182. The stock has underperformed, dropping 15.27% despite the bullish target of 182.

NRIX

Jun 08, 2026

Target

$45.00

Current

$25.10

Performance

60.49%

On Jun 08, 2026, NRIX was given a Buy rating by Roger Song, with a target price of 45. The stock rallied 60.49% after the rating, narrowing the gap to the target of 45 and validating the bullish stance.

SABS

May 20, 2026

Target

$11.00

Current

$3.41

Performance

-7.34%

SABS received a Buy rating from Roger Song on May 20, 2026, aiming for 11. The rating hasn’t played out as hoped, with the stock trading 7.34% below expectations.

KLRA

May 12, 2026

Target

$48.00

Current

$13.94

Performance

-37.49%

On May 12, 2026, Roger Song published a Buy outlook on KLRA, with a target of 48. Market action contradicted the Buy thesis, as shares slipped to 13.94.

KNSA

Apr 28, 2026

Target

$71.00

Current

$76.27

Performance

41.63%

Roger Song on Apr 28, 2026 assigned KNSA a Buy rating, with a price target of 71. The Buy call aligned well with market performance, producing a gain of 41.63%.

ALLO

Apr 15, 2026

Target

$10.00

Current

$1.78

Performance

—

On Apr 15, 2026, Roger Song reaffirmed ALLO with a Buy rating, targeting 10. Market indecision has kept the 10 target in a holding pattern.

REPL

Apr 13, 2026

Target

$2.00

Current

$12.92

Performance

660.00%

REPL was rated Hold by Roger Song on Apr 13, 2026, with a price objective of 2. Despite caution, upside momentum rewarded risk-takers with gains to 12.92.

CTMX

Mar 18, 2026

Target

$16.00

Current

$3.29

Performance

-25.23%

On Mar 18, 2026, Roger Song initiated coverage on CTMX with a Buy rating and target of 16. The Buy call has yet to be validated as shares remain 12.71 away from the target.

BIOA

Feb 18, 2026

Target

$62.00

Current

$8.49

Performance

-56.66%

Roger Song issued a Buy recommendation for BIOA on Feb 18, 2026, price target set at 62. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

KRYS

Feb 17, 2026

Target

$371.00

Current

$347.00

Performance

20.55%

On Feb 17, 2026, KRYS was evaluated by Roger Song, who gave a Buy rating and target of 371. This case illustrates how a timely bullish rating can translate into tangible gains of 20.55%.

PTGX

Feb 02, 2026

Target

$118.00

Current

$148.18

Performance

78.42%

Roger Song rated PTGX as Buy on Feb 02, 2026, setting a price target of 118. The call has proven timely, with shares rising 78.42% toward the price target of 118.

CRVS

Jan 22, 2026

Target

$42.00

Current

$12.91

Performance

-49.41%

On Jan 22, 2026, CRVS was given a Buy rating by Roger Song, with a target price of 42. Despite the Buy call, shares fell from 12.91 to 12.91, challenging the optimistic stance.

NKTR

Nov 26, 2025

Target

$121.00

Current

$69.76

Performance

6.20%

NKTR received a Buy rating from Roger Song on Nov 26, 2025, aiming for 121. Momentum has favored the Buy call, with shares climbing from 69.76 to 69.76, rewarding those who trusted the recommendation.

ORKA

Nov 13, 2025

Target

$45.00

Current

$92.38

Performance

250.19%

On Nov 13, 2025, Roger Song published a Buy outlook on ORKA, with a target of 45. Shares gained 250.19%, underscoring the accuracy of the bullish outlook toward 45.

GYRE

Oct 10, 2025

Target

$16.00

Current

$6.73

Performance

-15.45%

Roger Song on Oct 10, 2025 assigned GYRE a Buy rating, with a price target of 16. The call has struggled to gain traction, with shares losing 15.45%.

TRML

Sep 09, 2025

Target

$47.50

Current

$47.98

Performance

0.71%

On Sep 09, 2025, Roger Song reaffirmed TRML with a Hold rating, targeting 47.5. The neutral call matched muted market action of 0.71%.

UTHR

Sep 02, 2025

Target

$564.00

Current

$497.11

Performance

22.80%

UTHR was rated Buy by Roger Song on Sep 02, 2025, with a price objective of 564. A bullish response from the market helped close the gap of 66.89 to the target.

BMEA

Aug 28, 2025

Target

$5.00

Current

$1.74

Performance

-9.37%

On Aug 28, 2025, Roger Song initiated coverage on BMEA with a Buy rating and target of 5. The Buy call has yet to be validated as shares remain 3.26 away from the target.

ATYR

Aug 22, 2025

Target

$17.00

Current

$0.43

Performance

-91.97%

Roger Song issued a Buy recommendation for ATYR on Aug 22, 2025, price target set at 17. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

MBX

Aug 15, 2025

Target

$36.00

Current

$59.02

Performance

300.95%

On Aug 15, 2025, MBX was evaluated by Roger Song, who gave a Buy rating and target of 36. This case illustrates how a timely bullish rating can translate into tangible gains of 300.95%.

LVTX

Aug 05, 2025

Target

$1.50

Current

$1.74

Performance

15.23%

Roger Song rated LVTX as Hold on Aug 05, 2025, setting a price target of 1.5. Despite the Hold call, shares climbed 15.23% to 1.74, revealing unexpected momentum.

VERV

Jun 18, 2025

Target

$11.00

Current

$11.13

Performance

0.09%

On Jun 18, 2025, VERV was given a Hold rating by Roger Song, with a target price of 11. Market indecision, reflected in sideways trading near 11.13, supported the cautious call.

CVAC

Jun 13, 2025

Target

$5.00

Current

$4.66

Performance

-16.34%

CVAC received a Hold rating from Roger Song on Jun 13, 2025, aiming for 5. The Hold stance proved prudent, with the market softening by 16.34%.

AKBA

Apr 01, 2025

Target

$6.00

Current

$0.95

Performance

-50.17%

On Apr 01, 2025, Roger Song published a Buy outlook on AKBA, with a target of 6. Market action contradicted the Buy thesis, as shares slipped to 0.9517.

SANA

Mar 14, 2025

Target

$7.00

Current

$3.13

Performance

6.83%

Roger Song on Mar 14, 2025 assigned SANA a Buy rating, with a price target of 7. The Buy call aligned well with market performance, producing a gain of 6.83%.

WVE

Feb 25, 2025

Target

$26.00

Current

$4.59

Performance

-55.69%

On Feb 25, 2025, Roger Song reaffirmed WVE with a Buy rating, targeting 26. Shares slid 55.69% despite the recommendation, highlighting downside risks.

IGMS

Jan 10, 2025

Target

$2.00

Current

$1.27

Performance

-39.23%

IGMS was rated Hold by Roger Song on Jan 10, 2025, with a price objective of 2. Investors who stayed cautious avoided some of the 39.23% decline.

KURA

Nov 21, 2024

Target

$28.00

Current

$11.39

Performance

13.22%

On Nov 21, 2024, Roger Song initiated coverage on KURA with a Buy rating and target of 28. The stock’s climb of 13.22% since the call highlights the foresight in the rating.

ACRS

Nov 19, 2024

Target

$7.00

Current

$5.32

Performance

15.90%

Roger Song issued a Buy recommendation for ACRS on Nov 19, 2024, price target set at 7. Investors following the Buy call captured upside momentum, with shares now at 5.32.

NVAX

Oct 16, 2024

Target

$25.00

Current

$9.42

Performance

-7.19%

On Oct 16, 2024, NVAX was evaluated by Roger Song, who gave a Buy rating and target of 25. Investors saw limited payoff as shares fell short of the 25 target.

ZBIO

Oct 08, 2024

Target

$35.00

Current

$31.12

Performance

75.92%

Roger Song rated ZBIO as Buy on Oct 08, 2024, setting a price target of 35. The call has proven timely, with shares rising 75.92% toward the price target of 35.

PCVX

Sep 03, 2024

Target

$129.00

Current

$59.47

Performance

-46.01%

On Sep 03, 2024, PCVX was given a Buy rating by Roger Song, with a target price of 129. Despite the Buy call, shares fell from 59.47 to 59.47, challenging the optimistic stance.

Frequency Asked Questions

Who is Roger Song?

Roger Song is an analyst from Jefferies specializing in the Healthcare sector.

What is Roger Song's success rate?

Roger Song currently has a success rate of +64.21%.

How many ratings has Roger Song issued?

Roger Song has issued 16 stock ratings so far.

What is the average return of Roger Song's calls?

Their stock ratings have generated an average return of +54.04%.

What is Roger Song's ranking?

Roger Song is ranked #862 out of 4773 analysts.

What types of ratings does Roger Song give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Roger Song?

You can follow Roger Song by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Roger Song?

Their latest rating was a Buy on MANE issued on 2026-07-07.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep